22nd week of 2013 patent applcation highlights part 47 |
Patent application number | Title | Published |
20130137727 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES - Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. | 2013-05-30 |
20130137728 | Compositions and Methods for the Treatment of Degenerative Diseases - Disclosed are compounds or pharmaceutically acceptable salts thereof, having the structure of formula I. Also disclosed are methods of preventing and/or treating degenerative disease in a subject, comprising administering to said subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions for preventing and/or treating de-generative disease in a subject comprising a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof. | 2013-05-30 |
20130137729 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE - The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising
| 2013-05-30 |
20130137730 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1E - There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1δ and casein kinase 1ε. In addition, the present inhibitor inhibits casein kinase 1δ and casein kinase 1ε, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1δ or casein kinase 1ε is associated. There is further provided a pharmaceutical agent useful for the treatment of particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. | 2013-05-30 |
20130137731 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME - The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treatingh depression by administering the ethanamine compound. | 2013-05-30 |
20130137732 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF - This disclosure provides generally for antimicrobial compositions and methods for reducing or preventing microorganism growth, viability, or survival, which are useful for treating poultry, meat, seafood, vegetables, legumes, fruit, crops, and other products for human or animal consumption. For example, the compositions can include GRAS (Generally Recognized As Safe) antimicrobial components such as ε-poly-L-lysine in combination with at least one quaternary ammonium salt, including an aliphatic heteroaryl ammonium salt such as cetylpyridinium chloride. | 2013-05-30 |
20130137733 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses - This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment. | 2013-05-30 |
20130137734 | Polymorphs of an Active Pharmaceutical Ingredient - The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions camprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat. | 2013-05-30 |
20130137735 | CRYSTALLINE FORM OF 4- [5 - [3 -CHLORO-5 - (TRIFLUOROMETHYL) PHENYL] -4, 5 - DIHYDRO - 5 - (TRIFLUOROMETHYL) -3 - ISOXAZOLYL] -N- [2-0X0-2- [ ( 2, 2, 2 - TRIFLUOROETHYL) AMINO] ETHYL] -1- NAPH-THALENECARBOXAMIDE - Disclosed is a solid form of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide (Compound 1). Also disclosed are compositions containing a solid form of Compound 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a solid form of Compound 1 or a composition containing a solid form of Compound 1. | 2013-05-30 |
20130137736 | Methods for Treating Degenerative Diseases/Injuries - Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal. | 2013-05-30 |
20130137737 | HIGHLY CRYSTALLINE VALSARTAN - The present invention describes a highly crystalline form of valsartan, pharmaceutical compositions thereof and process for the preparation thereof. | 2013-05-30 |
20130137738 | FUNGICIDAL COMPOSITIONS FOR TURF TREATMENT AND IMPROVEMENT - The present invention relates to novel compositions comprising: a fungicide that inhibits mitochondrial respiration at the QoI site (QoI inhibitor), a contact fungicide, a demethylation inhibitor, and pigments, which are highly suitable for controlling unwanted phytopathogenic fungi. Moreover, the fungicidal compositions are able to control mold and fungus infection in grasses and in particular turf grasses. | 2013-05-30 |
20130137739 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND - A solid dispersion comprising a poorly soluble pharmaceutical compound, such as 3-methoxy-1,5-bis(4-methoxyphenyl)-1H-1,2,4-triazole, which has excellent ease of handling and stability is provided. The solid dispersion comprises a polymeric carrier (for example, a polymer selected from a group consisting of polyvinylpyrrolidone and copolyvidone) and further comprising hydroxypropyl methylcellulose as desired. | 2013-05-30 |
20130137740 | COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER - The present invention relates to specific analogs of combretastatin, in particular the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising the compounds, as well as their medical use, in particular in the treatment or prevention of cancer, including multidrug-resistant cancer. | 2013-05-30 |
20130137741 | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye - The present invention relates to development of efficacious pharmaceutical compositions in the form of aqueous solutions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000. | 2013-05-30 |
20130137742 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein. | 2013-05-30 |
20130137743 | AMORPHOUS AND A CRYSTALLINE FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE - The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described. | 2013-05-30 |
20130137744 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS - In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. | 2013-05-30 |
20130137745 | STABILIZED STATIN FORMULATIONS - The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same. | 2013-05-30 |
20130137746 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 2013-05-30 |
20130137747 | DOUBLE-STRANDED RNA-BASED NANOPARTICLES FOR INSECT GENE SILENCING - Nanoparticles for insect RNAi via oral delivery are provided, along with methods of silencing a target gene in a target insect using RNAi are provided. The nanoparticles comprise a polymer matrix and insect dsRNA. The dsRNA comprises at least one sequence having a region of complementarity substantially complementary to at least a portion of an mRNA transcript of the target gene. Insect baits comprising the nanoparticles are also provided. Methods of screening target gene functions are also provided using the methods disclosed herein. | 2013-05-30 |
20130137748 | WHSC1 AND WHSC1L1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS - Objective methods for diagnosing a predisposition to developing cancer, for example, bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma, are described herein. In one embodiment, the diagnostic method involves determining an expression level of a WHSC1 or WHSC1L1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of WHSC1 or WHSC1L1 associated disease, such as a cancer, e.g., bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of WHSC1 or WHSC1L1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions including them. Also, disclosed are methods of identifying substances for treating or/and preventing lung cancer, using as an index their effect on expression of a WHSC1 or WHSC1L1 gene, or a biological activity of a WHSC1 or WHSC1L1 polypeptide. | 2013-05-30 |
20130137749 | Compositions and Methods for Gene Silencing - Compositions and methods for modulating the expression of a protein of interest are provided. | 2013-05-30 |
20130137750 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF - The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection. | 2013-05-30 |
20130137751 | TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF. | 2013-05-30 |
20130137752 | RNA Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (siNA) - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression. | 2013-05-30 |
20130137753 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF BREAST CANCER - Embodiments of the present disclosure relate to methods and compositions for the diagnosis and treatment of breast cancer. In some embodiments, the present disclosure relates to the use of Merlin, OPN and particular microRNAs for evaluating the presence of breast cancer in a subject and for identifying therapeutic compounds. | 2013-05-30 |
20130137754 | TUMOR THERAPY WITH REPLICATION COMPETENT SINDBIS VIRAL VECTORS - Disclosed herein are methods for treating a mammal harboring a solid tumor which expresses higher levels of High Affinity Laminin Receptors (LAMR) than normal cells of the same lineage comprising systematically administering to a mammal in need of such treatment a therapeutically effective amount of a Replication Competent (RC) Sindbis virus vector, wherein said vector encodes a suicide gene. | 2013-05-30 |
20130137755 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI - The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same. | 2013-05-30 |
20130137756 | MODULATION OF HUMAN MOUSE DOUBLE MINUTE 2 HOMOLOG ACTIVITY - The invention is directed to isolated genomic polynucleotide fragments that encode human carboxypeptidase M and human mouse double minute 2 homolog, vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human carboxypeptidase M and human mouse double minute 2 homolog and to diagnose, treat, prevent and/or ameliorate a pathological disorder. | 2013-05-30 |
20130137757 | INHIBITOR OF INFLUENZA VIRUS INFECTION - An effective inhibitor of influenza virus infection on cells can be achieved by safety components for humans. The inhibitor of influenza virus infection consists of pectin and polynucleotide as main components and has an effect that inhibits adhesion between hemagglutinin and sialic acid. | 2013-05-30 |
20130137758 | AKT ACTIVITY SPECIFICALLY INHIBITING POLYPEPTIDE - The present invention is to provide a polypeptide specifically inhibiting the activity of Akt (Protein Kinase B), the DNA thereof, the antibody thereof, an inhibitor of Akt activity or an antitumor agent, and the like. The polypeptide comprises polypeptides (SEQ ID NO: 1, 3, 5, 7, and 9 of the sequence listing) that contain an amino acid sequence corresponding to any of the position of amino acid residue 10-24 of human TCL1, amino acid residue 8-22 of human TCL1B, amino acid residue 5-19 of human MTCP1, and amino acid residue 9-24 of mouse or rat TCL1; and the derivatives. Further, the present invention includes DNA encording the polypeptide (SEQ ID NO: 2, 4, 6, 8 or 10 of the sequence listing), and the antibodies specifically binding to the polypeptides. The polypeptide of the present invention can be used for an inhibitor of Akt activity, an antitumor agent, or the like. | 2013-05-30 |
20130137759 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASE - The present invention features compositions and methods for treatment of parasitic diseases and cancer. The compositions include | 2013-05-30 |
20130137760 | GAMBOGIC AMINE, A SELECTIVE TRKA AGONIST WITH NEUROPROTECTIVE ACTIVITY - Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO | 2013-05-30 |
20130137761 | NEW COMPOUNDS FOR THE PREVENTION AND/OR TREATMENT OF OSTEOARTHROSIS - The present invention relates to new compounds which are inter alia derivable from hops for use in the treatment of (for treating)/prevention or healing of a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, in particular a disease which is associated with or characterized by degeneration and/or a destruction of cartilage (and/or for the prevention of aggrecan loss). Food products comprising these compounds for use in the treatment (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, in particular a disease which is associated with or characterized by degeneration and/or a destruction of cartilage, are also envisaged. | 2013-05-30 |
20130137762 | COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASE OR NEUROPATHOLOGICAL CONDITION - This invention relates to extracts and refined fractions of a traditional Chinese medicinal herb, | 2013-05-30 |
20130137763 | FUSED CYCLOOCTYNE COMPOUNDS AND THEIR USE IN METAL-FREE CLICK REACTIONS - The invention relates to fused cyclooctyne compounds, and to a method for their preparation. The invention also relates to a conjugate wherein a fused cyclooctyne compound according to the invention is conjugated to a label, and to the use of these conjugates in bioorthogonal labeling, imaging and/or modification, such as for example surface modification, of a target molecule. The invention further relates to a method for the modification of a target molecule, wherein a conjugate according to the invention is reacted with a compound comprising a 1,3-dipole or a 1,3-(hetero)diene. | 2013-05-30 |
20130137764 | Treatment of Sleep-Wake Disorders - This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R | 2013-05-30 |
20130137765 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES - The present invention relates to the use of nitric oxide releasing compounds for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies. | 2013-05-30 |
20130137766 | Compound Used to Prevent Diseases Caused by Aquaporin Deficiency - A compound used to prevent diseases caused by aquaporin deficiency, which is 18β-Glycyrrhetinic acid derivative. Said compound can not only prevent diseases caused aquaporin deficiency, but be able to prevent aquaporin (AQP) production and enhance skin function. Since AQPs have many advantages in skin cells, e.g. promoting water and glycerine molecular transportation, increasing skin elasticity and cuticle moisture, increasing the cell proliferation and cell migration, aquaporin can promote skin bather function and wound cicatrization. Therefore, said compound can be applied potentially as a medicinal cosmetic in skin medicine cosmetology, or as a new medical composition to treat diseases caused by AQP abnormality, such as urine concentration defect, wound healing slow down, corneal re-epithelialization slow down and etc. | 2013-05-30 |
20130137767 | Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid - The present invention is directed to methods and compositions for treating arthritis in a subject, comprising administering about 430 mg to about 12.4 g of docosahexaenoic acid (DHA) per day in a dosage form to the subject in need thereof, wherein the dosage form is substantially free of eicosapentaenoic acid (EPA) and substantially free of non-alpha tocopherol. | 2013-05-30 |
20130137768 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES - The present invention relates to the docosahexaenoatepanthenyl of the following formula: It also relates to a method for preparing same and to a pharmaceutical composition comprising same and to the use of same in the treatment or the prevention of cardiovascular diseases, in particular atrial fibrillation. | 2013-05-30 |
20130137769 | Injectable Preparations Of Diclofenac And Its Pharmaceutically Acceptable Salts - Injectable formulations of water-soluble salts of diclofenac, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route. | 2013-05-30 |
20130137770 | INTRAVENOUS OMEGA-3 FATTY ACID COMPOSITIONS & METHOD OF USE - The invention encompasses intravenous pharmaceutical compositions containing omega-3 fatty acids and methods of treating traumatic brain injury, traumatic spinal cord injury and/or stroke using these pharmaceutical compositions. | 2013-05-30 |
20130137771 | FATTY ACIDS FOR USE AS A MEDICAMENT - The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. | 2013-05-30 |
20130137772 | HYDROXYPOLYAMINE SALTS - A salt of a polyamine having the formula: | 2013-05-30 |
20130137773 | Chelator Stabilized Cationic Ammonium Compounds and Compositions Comprising the Same - Stabilized cationic ammonium compounds are described. The compounds are stabilized with pyridine-based chelators and/or heteroketo-based chelators that impede the generation of nitrogen comprising groups from the cationic ammonium compounds. | 2013-05-30 |
20130137774 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX - This application describes pharmaceutical compositions, commercial packages, and methods for inhibiting cell proliferative disorders, especially those disorders, including Her2 related cancers, characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, and methods for imaging an HER-2 expressing tumor. | 2013-05-30 |
20130137775 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYSTEMIC AA AMYLOID DISEASES - Bis- and tris-dihydroxyaryl compounds their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially AA amyloidosis, and the manufacture of medicaments for such treatment. | 2013-05-30 |
20130137776 | METHOD FOR INHIBITING HISTONE GENE TRANSCRIPTION AND EXPRESSION - A method for inhibiting at least one of histone gene transcription and histone expression in a subject is provided. The method comprises administrating to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof: | 2013-05-30 |
20130137777 | FOAMING ALCOHOL COMPOSITIONS WITH SELECTED DIMETHICONE SURFACTANTS - Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products. | 2013-05-30 |
20130137778 | PROCESS TO PRESERVE AQUEOUS PREPARATIONS OF MINERAL MATERIALS, PRESERVED AQUEOUS PREPARATIONS OF MINERAL MATERIALS AND USE OF PRESERVATIVE COMPOUNDS IN AQUEOUS PREPARATIONS OF MINERAL MATERIALS - The present invention refers to a process for preserving an aqueous preparation of mineral material like e.g. calcium carbonate preparations, and to the use of a composition as a preservative in an aqueous preparation of mineral materials. | 2013-05-30 |
20130137779 | PROCESS TO PREPARE SURFACE-MODIFIED MINERAL MATERIAL, RESULTING PRODUCTS AND USES THEREOF - The present invention refers to a process to modify at least part of the surface of at least one mineral material, and to the use, as an additive in an aqueous suspension of mineral materials having a pH between 5 and 10, of at least one agent, wherein the additive allows for the formation of a low volume, high solids content filter or centrifuge cake on dewatering the suspension. | 2013-05-30 |
20130137780 | NON-ADHESIVE ELASTIC GELATIN MATRICES - The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making the non-adhesive elastic gelatin matrix. | 2013-05-30 |
20130137781 | PHARMACEUTICAL PREPARATION FOR CONTROLLING WATER-SOLUBLE DRUG RELEASE - A solid formulation comprising a water-soluble drug and a hardly water-soluble pharmaceutically-acceptable solid substance, which comprises silicone as a carrier, wherein the silicone formulation can exhibit an excellent controlled-release of the water-soluble drug. | 2013-05-30 |
20130137782 | METHOD OF PRODUCING COMPOSITION HAVING CONTINUOUS PHASE AND DISPERSE PHASE DISPERSED FINELY IN THE CONTINUOUS PHASE AND APPARATUS FOR PRODUCING THE COMPOSITON - There is provided a method of producing a composition having a continuous phase and a disperse phase dispersed finely with low polydispersity in the continuous phase, with high production efficiency. | 2013-05-30 |
20130137783 | STORAGE OF INTERMITTENT RENEWABLE AS FUEL USING CARBON CONTAINING FEEDSTOCK - A method and system for converting intermittent renewable energy and renewable carbonaceous feedstock to non-intermittent renewable electrical and thermal energy, storing it as fuels and chemicals and using it to capture and re-use or dispose of CO | 2013-05-30 |
20130137784 | GRAFT COPOLYMERS - Graft copolymers of hydrophobic polymers and hydrophilic polymers, a method for their preparation, and their use in membranes for medical treatments such as hemodialysis, hemodiafiltration and hemofiltration, in membranes for water purification, and in membranes for bioprocessing. | 2013-05-30 |
20130137785 | METHOD OF DEVULCANIZING A CROSS-LINKED ELASTOMERIC MATERIAL - A thermoset cross-linked elastomer material, such as scrap tire rubber, is devulcanized by subjecting the material to a mechanical mixing process in the presence of 0.5 to 2% by wt. of an organic catalyst having a thiol terminus. | 2013-05-30 |
20130137786 | PROCESS FOR RECYCLING AND DE-VULCANIZING RUBBER - The process for recycling and de-vulcanizing vulcanized rubber comprises the steps of: grinding said rubber in a mill in order to shred it into particles having a size substantially comprised between 5 and 15 mm; introducing the particles in an initial section of a two-screw co-rotating extruder having a length 64 times or more the external diameter of the screws, mixing the particles within the extruder, which is kept at a temperature comprised between 35 and 350° C., due to the screw rotation at a speed comprised between 15 and 300 rpm; and obtaining an extruded product formed by de-vulcanized rubber. | 2013-05-30 |
20130137787 | Reducing Emissions in Polyurethane Foam - This invention disclosure relates to a process to make flexible open cell polyurethane foam with optimum mechanical properties and lowest chemical emissions. Using the selection of tertiary amine catalysts together with a group of carboxylic acids according to this disclosure can produce foam products with optimum properties and lowest chemical emanations. | 2013-05-30 |
20130137788 | POROUS FILM - The invention provides a porous film including a polylactic acid based resin (A), a thermoplastic resin (B) that is not a polylactic acid based resin, and a filler (C), wherein resin (A) and resin (B) account for 10 to 95 mass % and 5 to 90 mass %, respectively, of the sum total 100 mass % of resin (A) and resin (B), while the filler (C) accounts for 1 to 400 parts by mass of the sum total 100 parts by mass of resin (A) and resin (B), with the porosity being 1 to 80%. The present invention provides a polylactic acid based porous film that has high flexibility, moisture permeability, heat resistance, and bleed-out resistance. | 2013-05-30 |
20130137789 | POLYVINYL CHLORIDE COMPOSITIONS - A polyvinyl chloride composition having polyvinyl chloride resin and a plasticizer ester selected from di-butyl terephthalate, di-isobutyl terephthalate, or mixtures thereof. | 2013-05-30 |
20130137790 | Impact-Resistant Foam Composition - A foam composition is provided. An exemplary foam composition comprises a polymer of styrene, ethylene, and butylene. The exemplary foam composition further comprises additional agents that enhance the foam composition's stability during industrial laundering and usage. As characterized by a peak tangent δ value around 19 degrees Celsius and a specific gravity below 0.16 g/cc, the foam composition is impact-resistant, lightweight, and resistant to shrinkage. Examples of the foam composition may be incorporated into garments as part of impact-resistant athletic attire. | 2013-05-30 |
20130137791 | POLYISOCYANURATE COMPOSITION - Polyisocyanurate foam composition, articles comprising the composition and a method of making the composition are described. The polyisocyanurate foam composition comprises the reaction product of a polyisocyanate compound; and a first polyester polyol comprising the residue of orthophthalic acid; a second polyester polyol comprising the residue of terephthalic acid; at least one polyether polyol having a functionality of at least 3 and a hydroxyl number greater than 200; and a physical blowing agent, wherein the isocyanate index is greater than 250. | 2013-05-30 |
20130137792 | METHOD FOR PREPARING AN ORGANOPOLYSILOXANE COMPOUND AND CURING COMPOSITION USING THE COMPOUND - A method for preparing an organopolysiloxane compound by mixing (A) an organopolysiloxane of the formula (1): | 2013-05-30 |
20130137793 | Construction Coating Compositions And Methods Of Applying The Same - A composition for use in construction comprising pigment, dry cement and at least 30% powder polymer is provided. The composition has enhanced color retention and abrasion resistance and when applied to a surface the composition produces a smooth or textured, water-shedding properties that are aesthetically-pleasing. The coated surface as well as the method of preparing and applying the composition is also provided. | 2013-05-30 |
20130137794 | PROCESS FOR MANUFACTURING AN ADHESIVE BY MEANS OF EXTRUSION - The present invention relates to a process for manufacturing an adhesive by extrusion, wherein the adhesive comprises at least one degraded polypropylene(co)polymer and at least one additional additive. | 2013-05-30 |
20130137795 | EPOXYSILICONE CONDENSATE, CURABLE COMPOSITION COMPRISING CONDENSATE, AND CURED PRODUCT THEREOF - There is provided an epoxy group-containing silicone condensate that yields cured products with excellent transparency, thermal resistance and gas barrier properties. An epoxysilicone condensate which is the product of hydrolytic condensation of an epoxy group-containing alkoxysilane compound represented by formula (1): | 2013-05-30 |
20130137796 | Epoxy Adhesive - Room temperature curing epoxy adhesives that show good adhesion to plastic substrates are described. The adhesives contain an epoxy resin component comprising a first epoxy resin and a second epoxy resin; a first amine curing agent having an equivalent weight of at least 50 grams per mole of amine equivalents; a second amine curing agent having an equivalent weight of no greater than 45 grams per mole of amine equivalents; an acetoacetoxy-functionalized compound; a metal salt catalyst; and a multifunctional acrylate. | 2013-05-30 |
20130137797 | POLYESTER COMPOSITIONS AND INSERT-MOLDED ARTICLES MADE THEREFROM - A thermoplastic polyester composition comprises polyalkylene terephthalate, a block copolymer comprising a semi-crystalline polyolefin block and at least one of a vinyl aromatic polymer block and an elastomeric polyolefin block, and reinforcing filler. The composition is capable of providing insert-molded articles, comprising a metal part, with high durability and resistance to cracking when subjected to a rigorous thermal cycle. | 2013-05-30 |
20130137798 | MANUFACTURING A COMPOSITE MATERIAL COMPRISING LIGNOCELLULOSIC FIBERS IN A PLASTIC MATRIX - A manufacturing method includes the steps of providing lignocellulosic fibers, providing a plastic material, and mixing the lignocellulosic fibers and the plastic material to obtain a composite material. The manufacturing method also includes, prior to the mixing step, a step for heat treatment of the lignocellulosic fibers wherein the lignocellulosic fibers are heated. | 2013-05-30 |
20130137799 | Graft copolymers - Anionic graft copolymers and scale inhibition compositions including the anionic graft copolymers in which the anionic graft copolymers include a natural component grafted with an ethylenically unsaturated anionic monomer where the anionic graft copolymer includes 1 or more reacted anhydroglucose units per every 100 anhydroglucose units in the anionic graft copolymer. | 2013-05-30 |
20130137800 | PHOSPHINIC ACID HYDRAZIDE FLAME RETARDANT COMPOSITIONS - The invention relates to flame retardant compositions, wherein a phosphinic acid hydrazide is present in a polymer substrate. The combination with >NOR-compounds improves the flame retardant properties. | 2013-05-30 |
20130137801 | Flame Retardant Polycarbonate Resin Composition and Molded Product Made Using the Same - A flame retardant polycarbonate resin composition that can have excellent scratch resistance and impact resistance includes: (A) about 10 to about 89 wt % of a polycarbonate resin; (B) about 10 to about 89 wt % of a polycarbonate-polysiloxane copolymer; (C) about 1 to about 70 wt % of a modified (meth)acrylic copolymer resin; and (D) about 1 to about 50 parts by weight of a phosphorus-based flame retardant, based on about 100 parts by weight of components (A)+(B)+(C). | 2013-05-30 |
20130137802 | RESIN COMPOSITION - A resin composition containing: an ester compound including a carboxylic acid ester obtained by using (1) a monohydric alcohol having an alkyl group having 1 to 4 carbon atoms; (2) a dicarboxylic acid having an alkylene group having 2 to 4 carbon atoms; and (3) a dihydric alcohol having an alkylene group having 2 to 6 carbon atoms, the ester compound having an acid value of 1.00 mgKOH/g or less, a hydroxyl value of 5.0 mgKOH/g or less, and a number-average molecular weight of from 300 to 700; and an aliphatic polyester. Since the resin composition of the present invention inhibits the generation of volatile compounds, the resin composition can be suitably used in various industrial applications, such as daily sundries, household electric appliance parts, and automobile parts. | 2013-05-30 |
20130137803 | LOW-CHARGING FIBER AND METHOD FOR PRODUCING THE SAME - An object to be achieved by the invention is to provide a biodegradable low-charging fiber. The prevent inventors have found that when a specific amount of a specific phospholipid that is not known to have antistatic properties is added to a biodegradable polymer, and the resulting mixture is formed into a fiber having a smooth surface, low-charging properties are developed. The invention has thus been accomplished. The invention is a fiber having an average surface porosity of less than 3% and made of a biodegradable polymer that contains a specific amount of a specific phospholipid. | 2013-05-30 |
20130137804 | POLY(ALIPHATIC ESTER)- POLYCARBONATE COPOLYMER/POLYLACTIC ACID BLEND - The present invention is directed to a blended composition comprising one or more polycarbonates wherein at least one of the polycarbonates is a polyesterpolycarbonate having at least one unit derived from a soft block ester unit, e.g., sebacic acid, and at least one unit derived from bisphenol A, and a polylactic polymer wherein the composition has an overall biocontent of at least 10% according to ASTMD6866 | 2013-05-30 |
20130137805 | REUSABLE PRINT MEDIUM AND METHOD OF MANUFACTURING THEREOF - The present invention relates to a reusable print medium comprising a substrate and a sacrificial layer. The sacrificial layer contains a hotmelt composition at least comprising an amorphous material. The amorphous material is a resin being a reaction product of a first monomer A, said first monomer A being a polyhydroxyl alcohol comprising X hydroxyl functional groups, wherein X≧2, monomer A optionally comprises a primary or secondary amine functionality; a second monomer B, being an aromatic monocarboxylic acid; a third monomer C, said third monomer C being able to form an ester linkage with an alcohol and/or an amide linkage with a primary or secondary amine; and optionally, a fourth monomer D, being an aromatic monocarboxylic acid different from the second monomer B. The sacrificial layer including the printed image may be removed from the substrate by applying heat. A new sacrificial layer may be applied such that the reusable print medium is ready to be reused. | 2013-05-30 |
20130137806 | PROCESS FOR PREPARING LIQUID OVERBASED METAL CARBOXYLATES, MIXED METAL STABILIZERS CONTAINING SAME, AND STABILIZED HALOGEN-CONTAINING POLYMERS THEREWITH - Liquid overbased alkali or alkaline earth metal carboxylates, particularly barium carboxylates, are prepared by a process which includes the use of a beta diketone as a reaction promoter during carbonation. Mixed metal stabilizers containing the overbased metal carboxylates are used as stabilizers for halogen-containing polymers such as polyvinyl chloride (PVC). | 2013-05-30 |
20130137807 | RUBBER COMPOSITION FOR INSULATION OF TIRE AND TIRE USING SAME - For the purpose of improving rolling resistance and durability, the present invention provides a rubber composition for insulation of a tire comprising 0.2 to 4 parts by mass of (B) an alkylphenol-sulfur chloride condensate, and 20 to 59 parts by mass of (C) carbon black having a BET specific surface area of 25 to 50 m | 2013-05-30 |
20130137808 | USE OF NANO ALUMINA OR SILICA DISPERSED IN POLYSTYRENE - Disclosed is a method of making a polystyrene based nanocomposite by combining a monomer with a nanoparticle to form a mixture and subjecting the mixture to polymerization conditions to produce a polymeric composite. In an embodiment the nanoparticle has been treated with an additive prior to combining with the monomer and the additive contains a silane moiety. | 2013-05-30 |
20130137809 | THERMOPLASTIC ELASTOMER COMPOSITION - A thermoplastic elastomer composition, and more particularly, a thermoplastic elastomer composition for use in manufacturing a joint connecting a glass run and an inner-belt. The thermoplastic elastomer composition includes an ethylene propylene diene monomer (EPDM), polybutene (PB), polypropylene (PP), paraffin oil, a peroxide cross-linking agent, and an antioxidant. | 2013-05-30 |
20130137810 | ACRYLIC ARTIFICIAL MARBLE HAVING GRANITE PATTERN AND METHOD OF MANUFACTURING THE SAME - The present invention relates to an acrylic artificial marble having a granite pattern and a method of manufacturing the same, which can provide a natural marble effect by mixing and molding two or more compounds having different colors and thus can obtain a granite pattern in which patterns of the two or more compounds are smoothly mixed, and which can obtain a desired pattern remarkably similar to a pattern of natural stone by using a multicolor chip sheet. | 2013-05-30 |
20130137811 | Modifying Polyoxymethylene Imidized Acrylic Resins - Described herein are compositions comprising (a) 92 to 99 weight percent, of polyoxymethylene with number average molecular weight from 65,000 to 250,000 g/mole; and (b) 1 to 8 weight percent of an imidized acrylic resin obtained by treating an acrylic polymer with a monoalkyl amine, wherein the weight percents of a and b are based on their combined weight, and monoalkyl group has from one to five carbon atoms, the degree of imidization is 20% to 100% and the acid level is from 0 to about 2 weight percent of the imidized acrylic resin. The composition has significantly higher heat deflection temperature than the neat polyoxymethylene. | 2013-05-30 |
20130137812 | BLENDED FLUOROPOLYMER COMPOSITIONS AND COATINGS FOR FLEXIBLE SUBSTRATES - Blended fluoropolymer compositions that, in one exemplary application, may be applied as a coating to a flexible substrate and, optionally, to a flexible substrate that has been previously coated with a primer or basecoat and/or a midcoat. In one embodiment, the composition is a blend of at least one low molecular weight polytetrafluoroethyelene (LPTFE) and at least one melt-processible fluoropolymer (MPF). In another embodiment, the composition includes a fluoropolymer base component including at least one fluoropolymer such as high molecular weight polytetrafluoroethylene (HPTFE), and additionally includes the LPTFE/MPF blended fluoropolymer composition. After being applied to the flexible substrate, optionally over a primer or basecoat and/or midcoat, and then cured, the present compositions form coatings that demonstrate improved abrasion resistance and/or improved release characteristics and/or increased translucency/transparency and/or improved impermeability. The present compositions may also be used to produce films having a high degree of clarity and impermeability. The present compositions in powder form may be melt or paste extruded to form articles with improved impermeability. | 2013-05-30 |
20130137813 | WATER-DISPERSED PRESSURE-SENSITIVE ADHESIVE COMPOSITION, PRESSURE-SENSITIVE ADHESIVE AND PRESSURE-SENSITIVE ADHESIVE SHEET - Provided is a water-dispersed pressure-sensitive adhesive composition capable of forming a pressure-sensitive adhesive that exhibits good adhesiveness to a non-polar adherend and maintains its properties at a low temperature. The water-dispersed pressure-sensitive adhesive composition according to the present invention comprises a (meth)acrylic polymer obtained by polymerizing a monomer composition containing as a primary component an alkyl (meth)acrylate having an alkyl group with 1 to 18 carbon atoms, a latex containing a rubber component that is immiscible with the (meth)acrylic polymer and has a loss tangent peak temperature of −5° C. or below when determined by a dynamic viscoelastic measurement in which shear strain is applied at a frequency of 1 Hz, and a tackifier that is miscible with the rubber component, but immiscible with the (meth)acrylic polymer. | 2013-05-30 |
20130137814 | RUBBER COMPOSITION - The present invention relates to a rubber composition comprising (A) an ethylene-α-olefin-based copolymer rubber, (B) a softening agent, and (C) an alkyl(meth)acrylate-based polymer. | 2013-05-30 |
20130137815 | INJECTION MOLDED PARTS PRODUCED FROM A POLYMER COMPOSITION COMPRISING POLYAMIDE 410 (PA-410) - Injection molded polymeric part produced from a polymer composition comprising polyamide 410 (PA-410) and less than 1.5 weight % of a mold release agent. In a preferred embodiment the polymer composition contains less than 1 wt. % of a mold release agent. | 2013-05-30 |
20130137816 | INK-JET INK COMPRISING CROSS-LINKED PIGMENT DISPERSION AND A POLYMERIC BINDER - The present disclosure provides an ink-jet ink containing an aqueous ink vehicle, an aqueous dispersion and a polymeric binder. The aqueous dispersion contains a colorant and a polyurethane dispersant, wherein the polyurethane dispersant is made with a polymer having cross-linkable moieties that are cross-linked with a cross-linking agent. | 2013-05-30 |
20130137817 | Cure-On-Demand Liquid Sealant Composition, Process For The Preparation Thereof And Uses Thereof - The present invention is directed to a liquid sealant composition based on polysulphide, capable of curing on demand, and the process for preparing same, the liquid sealant composition including: (i) a polysulphide comprising an —SH end group, (ii) a crosslinking agent chosen from ethylenically unsaturated or acetylenically unsaturated compounds, the unsaturated ethylenic or unsaturated acetylenic functions of the crosslinking agent being chemically blocked with a blocking agent, and (iii) optionally, a catalyst. The present invention also relates to a process for coating a substrate with a composition according to the invention, and also to the cured sealant materials formed from this composition. Finally, the invention relates to the use of a liquid sealant composition according to the invention for the construction and/or the maintenance, and more particularly for the adhesive bonding and/or the protection, of vehicles and machines. | 2013-05-30 |
20130137818 | POLYMERS HAVING CARBAZOLE STRUCTURAL UNITS - The present invention relates to polymers which contain at least one carbazole structural unit of the general formula (I) where Ar1, Ar2, Ar3 is each, independently of one another, an aryl or heteroaryl | 2013-05-30 |
20130137819 | INTEGRATED PROCESS FOR PRODUCING POLYVINYL ALCOHOL OR A COPOLYMER THEREOF AND ETHANOL - Ethanol is produced from methyl acetate by a hydrogenolysis reaction. The methyl acetate is produced as a byproduct during the conversion of a vinyl acetate polymer or copolymer to a polymer or copolymer of vinyl alcohol. By integrating the two processes, a valuable product, i.e. ethanol, is produced from a methyl acetate byproduct. | 2013-05-30 |
20130137820 | Process For Producing Polyvinyl Alcohol Or A Copolymer Thereof - Acetic acid is converted to vinyl acetate monomer by a reaction with oxygen and ethylene. The vinyl acetate is polymerized to form a vinyl acetate polymer or copolymer, which is then reacted in a methanolysis reaction with methanol and base to form a polymer or copolymer of vinyl alcohol and a methyl acetate byproduct. Ethanol is produced from methyl acetate by a hydrogenolysis reaction. The hydrogenolysis reaction also produces methanol. At least a portion of this ethanol is converted to ethylene by a dehydration reaction. At least a portion of the ethylene produced in this dehydration reaction is recycled to react with acetic acid and oxygen to form vinyl acetate. By converting a byproduct and by recycle of compositions, a polymer or copolymer of vinyl alcohol is efficiently produced with minimal waste. | 2013-05-30 |
20130137821 | AMPHIPHILIC MULTI-ARM COPOLYMERS AND NANOMATERIALS DERIVED THEREFROM - The present invention relates to polymers, nanomaterials, and methods of making the same. Various embodiments provide an amphiphilic multi-arm copolymer. The copolymer includes a core unit and a plurality of amphiphilic block copolymer arms. Each block copolymer arm is substituted on the core unit. Each block copolymer arm includes at least one hydrophilic homopolymer subunit and at least one hydrophobic homopolymer subunit. In some examples, the copolymer can include a star-like or bottlebrush-like block copolymer, and can include a Janus copolymer. Various embodiments provide a nanomaterial. In some examples, the nanomaterial can include Janus nanomaterials, and can include nanoparticles, nanorods, or nanotubes. The nanomaterial includes the amphiphilic multi-arm copolymer and at least one inorganic precursor. The inorganic precursor can be coordinated to at least one homopolymer subunit of one of the amphiphilic block copolymer arms to form the nanomaterial. Various embodiments also provide methods of making the copolymer and the nanomaterial. | 2013-05-30 |
20130137822 | MODIFIED CARBON NANOTUBES AND THEIR COMPATIBILITY - Modified carbon nanotubes are provided having carbon nanotube core covalently bound through C—C bonds to a polymer shell surrounding the carbon nanotube core. The polymer shell is a polymer having functional groups pointing outwardly from the shell. The functional groups are compatible with or able to covalently connect to another polymer. Such modified carbon nanotubes are more readily dispersed in a homogeneous manner in another polymer and may be used as a reinforcing filler in a polymer matrix. The modified carbon nanotubes with a core-shell structure in which the core has a substantially unidirectional orientation within the shell are produced by reacting neutral carbon nanotubes with 4-vinylaniline through a diazonium reaction in presence of one or more types of multifunctional monomers carrying a vinyl moiety and one or more functional groups for compatibilization with or connection to another polymer. The reaction is conducted at an elevated temperature without isolation of intermediates and without addition of any extra initiator or catalyst to form a polymer shell in situ around the carbon nanotube. The polymer shell is covalently bound to CNT sidewall through C—C bonds and has functional groups outwardly pointing from the shell for compatibilization with or connection to another polymer. | 2013-05-30 |
20130137823 | RESIN COMPOSITION COMPRISING ISOSORBIDE CONTAINING SATURATED POLYMER - The present invention relates to a resin composition comprising (a) an unsaturated polyester resin and/or a vinyl ester resin, (b) a reactive diluent and (c) a saturated polymer soluble in the reactive diluent, wherein the saturated polymer comprises isosorbide building blocks and has a molecular weight M | 2013-05-30 |
20130137824 | PREPARATION OF METALLIC COMONOMERS FOR POLYSTYRENE - A method for making a polystyrene ionomer comprises: preparing a metallic comonomer within styrene monomer to form a reaction mixture; and placing the reaction mixture under conditions suitable for the formation of a polymer composition. The metallic comonomer can be a metal acrylate, formed by contacting a metal complex and an acrylate precursor. | 2013-05-30 |
20130137825 | THERMOPLASTIC ELASTOMER COMPOSITION AND MEDICAL RUBBER PRODUCT - The present invention aims to provide a dynamically-crosslinked thermoplastic elastomer composition that can provide a molded product exhibiting low compression set especially in the case of being cooled under stress. The present invention relates to a thermoplastic elastomer composition, including a dynamically-crosslinked butyl rubber and a thermoplastic resin; and having a thermoplastic resin content of not more than 8% by mass. The dynamically-crosslinked butyl rubber is preferably a halogen-containing butyl rubber. | 2013-05-30 |
20130137826 | PROPYLENE-BASED POLYMER COMPOSITION AND USES THEREOF - The propylene-based polymer composition includes a specific amount of a propylene-based polymer (A) having a syndiotactic pentad fraction (rrrr fraction) of 85% or more and containing 90 to 100 mol % of a structural unit derived from propylene; a specific amount of a propylene-based copolymer (B) containing 40 to 89 mol % of a structural unit derived from propylene and 11 to 60 mol % of a structural unit derived from an α-olefin and satisfying a specific equation of intrinsic viscosity [η] and MFR; and specific amount(s) of at least one polymer of an olefin-based thermoplastic elastomer (C), a styrene-based elastomer (D), a propylene/ethylene/α-olefin copolymer (E) and an isotactic propylene-based polymer (F), and optionally an ethylene/vinyl acetate copolymer (G) and/or an ethylene-based polymer (H). | 2013-05-30 |